ProCE Banner Activity

CME

Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3–Targeted ADCs

Video

On-demand webcast of expert-faculty presentation and case discussion on implementing antibody–drug conjugates in lung cancer care to treat HER2-, HER3-, TROP2- and B7-H3–positive disease.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

European Learners: 1.00 EBAC® CE Credit

Released: October 22, 2024

Expiration: May 31, 2025

Share

Faculty

David Planchard

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

Egbert F. Smit

Egbert F. Smit, MD, PhD

Professor of Pulmonary Medicine
Department of Pulmonary Diseases
Leiden University Medical Center
Leiden, Netherlands

Helena Yu

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.

Target Audience

This program is intended for medical oncologists and other healthcare professionals caring for patients with lung cancer.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Non-Small Cell Lung Cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Evaluate current biomarker targets of ADCs for lung cancer treatment considering the rationale, abnormal expression or mutational status in lung cancers, and guidance on testing and pathological assessment

  • Differentiate important defining characteristics between ADC therapies and how these attributes may influence efficacy and safety outcomes

  • Select patients who may benefit from HER2-targeted ADC therapy considering patient-specific factors, such as overall health, comorbidities, prior treatments, and proper pathological assessment

  • Appraise emerging clinical data evaluating the use of ADCs for the treatment of NSCLC and SCLC

  • Develop protocols for regular patient monitoring during and after ADC treatment to detect and manage adverse events promptly

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

David Planchard, MD, PhD: consultant/advisor/speaker: AbbVie, ArriVent, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Janssen, Lilly, Merck, Mirati, Novartis, Pfizer, Pierre Fabre, Roche, Seagen, Takeda.

Egbert F. Smit, MD, PhD

Professor of Pulmonary Medicine
Department of Pulmonary Diseases
Leiden University Medical Center
Leiden, Netherlands

Egbert F. Smit, MD, PhD: consultant/advisor/speaker: AstraZeneca, Bayer, Bristol Myers Squibb, DSI, Lilly, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Takeda; researcher: AstraZeneca, Bristol Myers Squibb, DSI, Merck, Merck Sharp & Dohme, Roche.

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Helena Yu, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Black Diamond, Daiichi Sankyo, Janssen, Taiho.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 22, 2024, through May 31, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EBAC® Accreditation 

This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for up to 1.0 hour of external CE credit. Each participant should claim only those hours of credit that have actually been spent in the educational activity. 

The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on substantial equivalency of accreditation systems with EBAC®. 

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association, physicians may convert EBAC® CE credits/points to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™. 

Total effective education time: 90 mins 

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.